Hansa Biopharma AB: Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-announces-reimbursement-in-the-Netherlands-of-Idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/default.aspx
|
|
|
